TABLE 2.
Overview of clinical trials of various RBC-based formulations (Source: ClinicalTrials.gov).
| Technology/company | Disease | Clinical trial phase | Trial identifier | Status |
|---|---|---|---|---|
| Dexamethasone encapsulated in RBCs/EryDel | Ataxia telangiectasia | Phase 3 | NCT03563053 | Recruiting Chessa et al. (2014) |
| L-asparaginase encapsulated in RBCs/ERYtech Pharma | Acute lymphoblastic leukemia | Phase 2 | NCT01810705 | Completed Thomas and le Jeune. (2016) |
| — | Pancreatic ductal adenocarcinoma | Phase 3 | NCT03665441 | Active, not recruiting Hammel et al. (2020) |
| — | Triple-negative breast cancer | Phase 2/3 | NCT03674242 | Recruiting |
| Thymidine phosphorylase encapsulated within autologous erythrocytes/orphan technologies Ltd. | Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). | Phase 2 | NCT03866954 | Active, not recruiting |
| KAN-101/anokion | Celiac disease | Phase 1 | NCT04248855 | Completed |
| RTX-134/rubius therapeutics | Phenylketonuria | Phase 1 | NCT04110496 | Active, not recruiting |